News
The Association of Multisite Research Corporations (AMRC) today announces Pratia, one of the largest and most respected site networks, has joined as the association’s fifteenth member. With this addition, AMRC now represents a collective footprint of nearly 500 research sites, almost 8,000 employees, and approximately 1,500 principal investigators across its member companies, globally.
Hosted by AMRC, this timely webinar offered insights into the evolving federal policy and funding landscape affecting multisite clinical research corporations (MCRCs), with a strong focus on strategic advocacy and the challenges ahead.
WEBINAR - MARCH 26, 2025
The federal policy landscape is shifting—how will it impact multisite clinical research corporations (MCRCs)?
Join Patrick Cooney, a seasoned expert with bipartisan insight into healthcare policy, as we explore the federal government’s priorities and funding outlook for clinical research.
In a recent interview with E.B. McLindon, CEO of Helios Clinical Research and Director at the Association for Multi-Site Research Corporations (AMRC), McLindon shared his perspective on the mindset needed in the research industry
WEBINAR - JANUARY 23, 2025
Operational inefficiency in clinical research: what is it costing Sponsors and CROs?
The Association of Multisite Research Corporations (AMRC) welcomes a panel of experts to discuss the financial and operational impact of inefficiency in clinical trials. We’ll be joined by representatives from regulatory, academic, pharma, and trial sites, who will share their perspectives on the challenges facing the industry and possible solutions to streamline trials, improve data quality, and bring therapies to patients faster.
As part of AMRC's role to advocate for multisite clinical research corporations (MCRC), we responded to the FDA's consultation: Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices; Guidance for Industry - Draft Guidance.
The clinical trial ecosystem has become increasingly complex, with the number of drugs in development nearly doubling between 2012 and 2022. This growth, coupled with rising patient recruitment demands and the need for diverse trial endpoints, has highlighted the limitations of the traditional site model.
The traditional clinical trial model, which relies on independent sites and Principal Investigators (PIs), faces significant inefficiencies, including fragmented processes, delayed start-ups, administrative burdens, and high burnout rates. These inefficiencies contribute to trial delays, missed enrollment targets, and increased costs—estimated at $540,000 per day due to lost prescription sales and trial expenses.
The Association of Multisite Research Corporations (AMRC) has officially launched, marking a transformative step forward in clinical research. This new trade association aims to advance the adoption of multisite clinical research corporations (MCRCs) to enhance efficiency, improve patient safety, and uphold data integrity in clinical trials.
